Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 12/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594077 | 0.88 | APP (0.57) | APPSYK | |
| SCHEMBL3600524 | 0.81 | APP (0.62) | APPSYK | |
| SCHEMBL3607808 | 0.78 | APP (0.72) | APPSYKKDRPLK1 | |
| SCHEMBL1277196 | 0.76 | HTT (0.50) | — | |
| SCHEMBL3602388 | 0.75 | APP (1.00) | APPSYKJAK2 | |
| SCHEMBL3608443 | 0.73 | APP (0.58) | APPSYK | |
| SCHEMBL6016545 | 0.72 | SYK (0.66) | SYK | |
| SCHEMBL3581486 | 0.71 | APP (0.63) | APPSYK | |
| SCHEMBL3595281 | 0.71 | SYK (0.60) | APPSYK | |
| SCHEMBL1735275 | 0.71 | RAF1 (0.59) | APPSYKKDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | APP 2/4885PDE4B 1448/4885SYK 3311/4885 |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | APP 2/4885PDE4B 1448/4885SYK 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.